”With its late-stage investment activity, in contrast to venture investing, Novo will be creating value by holding rather than by exiting.”
Håkan Åström, member of the Novo Advisory Group
Going large, late and long ...
At Novo, our investment span is broader than any other devoted life science investor. From nurturing pre-seed projects to deploying significant capital as cornerstone investors in fully fledged enterprises, we play an active role as a committed shareholder as these continue to profitably build and grow.
…into well-established companies ...
Our large scale, late-stage investment activities are targeted towards well-established life science companies that have positive cash flow, strongly positioned products and attractive prospects. Our goal is to create value through active support and long-term ownership.
…for long-term value generation
These late-stage investments may amount to several billion DKK per company in exchange for influential equity ownership stakes in publicly listed as well as privately owned companies.